Navigation Links
Otix Global, Inc. to Discontinue German Operations
Date:9/13/2010

SALT LAKE CITY, Sept. 13 /PRNewswire/ -- Otix Global, Inc. (Otix) (Nasdaq: OTIX), a leading provider of hearing care services and solutions today announced that it has decided to discontinue its operations in Germany as of September 14, 2010.  In explaining this decision, Sam Westover, Chairman and CEO of Otix stated, "the regulatory obstacles in Germany have dramatically impacted the feasibility of stability of our business and, as a result, we have made the decision to discontinue our operations."

ABOUT OTIX GLOBAL:

Otix Global designs, develops, manufactures and markets advanced digital hearing aids designed to provide the highest levels of satisfaction for hearing impaired consumers.

This press release contains "forward-looking statements" as defined under securities laws. Actual results may differ materially and adversely from those described herein depending on a number of factors but not limited to, the following risks: the merger with William Demant Holding A/S (WDH) may not be approved by our shareholders or the applicable governmental agencies; we may fail to receive the requisite number of votes or proxies from our shareholders to obtain a quorum; the merger agreement may be terminated according to its terms prior to the finalization of the merger; the announcement of the pending merger with WDH may have a significant and deleterious effect on our business; deterioration of economic conditions could harm our business; we have a history of losses and negative cash flow; we face aggressive competition in our business, and if we do not compete effectively our net sales and operating results will suffer; our financial results may fluctuate significantly, which may cause our stock price to decline; we have made a number of acquisitions and could make additional acquisitions, which could be difficult to integrate, disrupt our existing business, dilute the equity of our shareholders, harm our operating results, and create tension within our existing customer bases; if we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud, and as a result, current and potential stockholders could lose confidence in our financial reporting, which could harm our business and the trading price of our common stock; the loss of any large customer or a reduction in orders from any large customer or buying groups could reduce our net sales and harm our operating results; we rely on several suppliers and contractors, and our business will be seriously harmed if these suppliers and contractors are not able to meet our requirements; we have high levels of product returns, remakes and repairs, and our net sales and operating results will be lower if these levels increase; if we fail to develop new and innovative products, our competitive position will suffer, and if our new products are not well accepted, our net sales and operating results will suffer; because of the complexity of our products, there may be undiscovered errors or defects that could harm our business or reputation; if we are subject to litigation and infringement claims, they could be costly and disrupt our business; we may be unable to adequately protect or enforce our proprietary technology, which may result in its unauthorized use or reduced sales or otherwise reduce our ability to compete; we are dependent on international operations, which exposes us to a variety of risks, that could result in lower sales and operating results; complications may result from hearing aid use, and we may incur significant expense if we are sued for product liability; if we fail to comply with Food and Drug Administration regulations or various sales-related laws, we may suffer fines, injunctions or other penalties; there may be sales of our stock by our directors and officers, and these sales could cause our stock price to fall; and we could default on our debt covenant on our line of credit. For additional information regarding the risks inherent in our business, please see "Factors That May Affect Future Performance" included in our Annual Report on Form 10-K for the year ended December 31, 2009, and Form 10-Qs for the quarters ended March 31, 2010 and June 30, 2010 as filed with the Securities and Exchange Commission.

We undertake no obligation to revise our forward-looking statements to reflect events or circumstances after the date hereof as a result of new information, future events or otherwise.


'/>"/>
SOURCE Otix Global, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Otix Global, Inc. Announces Reverse Stock Split
2. Otix Global, Inc. Extends Term of Loan and Security Agreement With Silicon Valley Bank
3. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
4. Replidyne Discontinues Phase III Trial
5. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
6. Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
7. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
8. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
9. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
10. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
11. German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... 2016 Research and ... Acute Myeloid Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia ...
Breaking Medicine Technology:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Multiple award ... been family-owned and operated for over 35 years. Maintaining core values of exceptional customer ... their success and made them a leading name in San Diego plumbing, and other ...
(Date:5/6/2016)... ... May 06, 2016 , ... In honor ... education and corporate training, and the National Military Family Association, a nonprofit that ... as the second full-tuition scholarship recipient of 2016. , “Being awarded this ...
(Date:5/6/2016)... ... 2016 , ... “ Crossing Over: Affirmations of Faith in the Midst of ... allowed those holding vigil to glimpse into the supernatural as their lives ended. With ... spiritually and practically gain insight into providing care to terminal patients. , “I ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is excited ... for public stakeholder review. The stakeholder review is an important opportunity for interested parties ... and delivers value to the wool industry., The RWS is intended to be a ...
Breaking Medicine News(10 mins):